CERo Therapeutics

CERo Therapeutics is developing next-generation cell therapies designed to overcome limitations of current immunotherapies by creating multifunctional T cells. Its proprietary CER platform engineers T cells to recognize 'Eat Me' signals on tumors, enabling them to engulf cancer cells, kill them directly, and present tumor antigens to stimulate a broader, secondary immune response. This integrated approach aims to enhance curative potential and safety, positioning CERo in the competitive but high-potential field of advanced cell therapies for oncology.

The Chimeric Engulfment Receptor (CER) platform engineers autologous T cells to integrate innate immune functions (phagocytosis, antigen presentation) with adaptive immune T-cell killing, creating multifunctional cells designed to attack cancer through multiple mechanisms.

Total raised: $77M

Competes with established CAR-T leaders in hematology and a crowded field of next-gen cell therapy developers targeting solid tumors. Key differentiation is the integration of phagocytic 'eating' capability and antigen presentation into a therapeutic T cell, a hybrid approach not yet commercialized.